Filter
767
Text search:
isoniazid
Featured
105
223
Language
Document type
557
101
47
30
9
8
7
4
3
1
Countries
46
33
28
27
25
22
22
20
20
16
14
14
12
12
11
9
9
8
8
8
8
7
7
6
6
6
5
5
5
5
5
4
4
4
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
309
89
17
16
15
9
7
Toolboxes
382
45
30
17
13
13
10
7
7
5
2
2
2
1
Moving avidence into action
This document is part of a series of briefs for health program managers interested in implementing evidence-based programs. With a special emphasis on underutilized interventions, they present evidence on programs that work and provide guidance and resources for replicat
...
HIV/TB Research Meeting; March 3, 2013
PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
Research
Emerging Infectious Diseases Vol. 12, No. 5, May 2006
Профілактичне лікування ізоніазидом. Що це таке?
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evi
...
This study aimed to determine the drug resistance profile of Mycobacterium tuberculosis in Mozambique and concludes that M. tuberculosis resistance to antituberculosis drugs is high in Mozambique, especially in previously treated patients. The frequency of M. tuberculosis strains that were resistant
...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for is
...
Of the more than 10 million people estimated to have fallen ill with tuberculosis (TB) in 2022, just over 400 000 people developed TB resistant to rifampicin (RIF), and 1.3 million people developed TB resistant isoniazid (INH). Drug resistance must
...
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rifampicin-resistant and multi-drug resistant T
...
